Insights Into Exact Sciences Corp. (EXAS) Exposure By Institutions

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Stocks Info

Exact Sciences Corp. is listed on the NASDAQ in the Healthcare sector while operating in the Diagnostics & Research industry. At the end of the last regular session, the stock closed at $70.41 and fluctuated between $70.50 as its day high and $67.05 as its day low. The current market capitalization of Exact Sciences Corp. is $12.78B. A total of 3.17 million shares were traded on the day, compared to an average of 2.02M shares.

In the most recent transaction, Condella Sarah sold 2,000 shares of EXAS for 70.00 per share on Mar 28 ’24. After the transaction, the EVP, Human Resources now owns 73,787 company shares. In a previous transaction on Mar 01 ’24, Conroy Kevin T sold 8,271 shares at 59.32 per share. EXAS shares that President and CEO owns now total 1,299,496.

Among the insiders who sold shares, LEVANGIE DANIEL J disposed of 5,000 shares on Mar 01 ’24 at a per-share price of $57.50. This resulted in the Director holding 22,975 shares of EXAS after the transaction. In another insider transaction, Cunningham Everett sold 2,412 shares at $59.32 per share on Mar 01 ’24. Company shares held by the Chief Commercial Officer now total 46,179.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, EXAS has a high of $100.77 and a low of $56.05.

As of this writing, EXAS has an earnings estimate of -$0.46 per share for the current quarter. EPS was calculated based on a consensus of 15 estimates, with a high estimate of -$0.17 per share and a lower estimate of -$0.63. The company reported an EPS of $0 in the last quarter, which was 100.00% higher than expectations of -$0.48.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. EXAS’s latest balance sheet shows that the firm has $1.03B in Cash & Short Term Investments as of fiscal 2021. There were $2.38B in debt and $517.07M in liabilities at the time. Its Book Value Per Share was $17.34, while its Total Shareholder’s Equity was $3.39B.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for EXAS is Buy with a score of 4.68.

Most Popular

Related Posts